Safety and Efficacy of Remote Ischemic Conditioning in Patients With Intravenous Thrombolysis: The SERIC-IVT Trial
Abstract
BACKGROUND:
Approximately half of the patients with acute ischemic stroke who receive intravenous thrombolysis (IVT) do not achieve an excellent outcome. Remote ischemic conditioning (RIC) as a promising neuroprotective treatment may improve clinical outcomes in this population. This study aimed to assess the efficacy and safety of RIC in patients with IVT.
METHODS:
This multicenter, participant-blinded, blinded end point, randomized controlled clinical trial included 558 patients with acute ischemic stroke who underwent IVT in 18 hospitals from August 2021 to May 2023. After IVT, patients were randomized 1:1 to the RIC (unilateral upper limb; cuff pressure, 200 mm Hg, twice daily for 7 days) or sham RIC groups (the same procedure; cuff pressure, 60 mm Hg). The primary efficacy outcome was an excellent functional outcome (modified Rankin Scale score, 0–1) at 90 days after IVT.
RESULTS:
In total, 558 eligible patients were randomized, and 11 (2.0%) were excluded because they did not receive an RIC or sham RIC. Thus, 547 patients (RIC, n=274; sham RIC, n=273) were included in the modified intention-to-treat analysis, of whom 15 patients were lost to follow-up and 532 (95.3%) completed the trial. At 90 days, 62.7% of patients in the RIC group and 56.8% in the sham RIC group had an excellent functional outcome (unadjusted risk ratio, 1.10 [95% CI, 0.96–1.27]; P=0.169). The proportion of patients with any adverse events was 11.2% in the RIC group and 8.1% in the sham RIC group, with no significant difference (P=0.221).
CONCLUSIONS:
RIC was safe in patients with acute ischemic stroke who received IVT. However, it did not significantly improve excellent functional outcome.
REGISTRATION:
URL: https://www.clinicaltrials.gov; Unique identifier: NCT04980625.
Graphical Abstract
Get full access to this article
View all available purchase options and get full access to this article.
Supplemental Material
Supplemental Methods
Tables S1–S6
Figure S1
SERIC-IVT Study Protocols
Statistical Analysis Plan
List of Committee Members
Collaborators
CONSORT Checklist
- Download
- 1.86 MB
Information & Authors
Information
Published In
Copyright
© 2025 American Heart Association, Inc.
History
Received: 11 July 2024
Revision received: 4 November 2024
Accepted: 26 November 2024
Published online: 8 January 2025
Keywords
Subjects
Authors
Funding Information
MOST | National Natural Science Foundation of China (NSFC) 501100001809: 82071291
Norman Bethune Health Science Center of Jilin University: 2022JBGS03
Science and Technology Department of Jilin Province: YDZJ202302CXJD061,20220303002SF
Jilin Provincial Key Laboratory: YDZJ202302CXJD017
the Talent Reserve Program of the First Hospital of Jilin University: JDYYCB-2023002
Metrics & Citations
Metrics
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
Purchase this article to access the full text.
eLetters(0)
eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.
Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.